發送短信 : Preclinical characteristics of the irreversible pan-HER kinase inhibitor neratinib compared with lapatinib : implications for the treatment of HER2-positive and HER2-mutated breast cancer

 _    _    _    _     _____     _____    __   __  
| \  / || | || | ||  / ____||  |  ___||  \ \\/ // 
|  \/  || | || | || / //---`'  | ||__     \   //  
| .  . || | \\_/ || \ \\___    | ||__     / . \\  
|_|\/|_||  \____//   \_____||  |_____||  /_//\_\\ 
`-`  `-`    `---`     `----`   `-----`   `-`  --`